The latest price target for Cocrystal Pharma (NASDAQ:COCP) was reported by HC Wainwright & Co. on January 22, 2025. The analyst firm set a price target for $7.00 expecting COCP to rise to within 12 months (a possible 241.46% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Cocrystal Pharma (NASDAQ:COCP) was provided by HC Wainwright & Co., and Cocrystal Pharma reiterated their buy rating.

There is no last upgrade for Cocrystal Pharma

There is no last downgrade for Cocrystal Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cocrystal Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cocrystal Pharma was filed on January 22, 2025 so you should expect the next rating to be made available sometime around January 22, 2026.

While ratings are subjective and will change, the latest Cocrystal Pharma (COCP) rating was a reiterated with a price target of $7.00 to $7.00. The current price Cocrystal Pharma (COCP) is trading at is $2.05, which is out of the analyst’s predicted range.